Table 2.

Effects of BMI and prognostic factors on overall survival after atezolizumab and bevacizumab in univariate and multivariate Cox regression models

	Univariate models		Multivariable models
	Hazard ratio (95% CI)	p value	Hazard ratio (95% CI)	p value
BMI 25+	1.00 (0.60–1.64)	0.98	0.72 (0.42–1.23)	0.23
BCLC stage (C vs A or B)	1.50 (0.89–2.52)	0.13	1.06 (0.57–1.97)	0.85
CTP class (B vs A)	3.01 (1.77–5.13)	< 0.001	2.44 (1.35–4.42)	0.003
Tumour size > 7 cm	1.30 (0.77–2.20)	0.32	1.04 (0.61–1.78)	0.89
MVI	2.51 (1.15–4.18)	< 0.001	1.87 (0.99–3.55)	0.05
Metastatic disease	0.80 (0.47–1.36)	0.41	0.88 (0.49–1.57)	0.66
AFP > 400 ng/dL	1.32 (0.79–2.19)	0.29	1.21 (0.71–2.05)	0.49

95% CI 95% confidence interval, BCLC Barcelona clinic liver cancer, CTP Child-Turcotte-Pugh, MVI Macrovascular invasion, AFP alpha-fetoprotein